Form 4: Marimed Chief Commercial Officer Reports Routine Stock Transactions Following RSU Vesting

Marimed Inc.'s Chief Commercial Officer, Ryan Crandall, reported the acquisition of 54,000 common shares through RSU conversion and the disposition of 18,711 shares for tax withholding, increasing his direct beneficial ownership.

Summary

• Ryan Crandall, Chief Commercial Officer of MARIMED INC. (MRMD), filed a Form 4 reporting changes in his beneficial ownership.
• On June 8, 2025, Mr. Crandall acquired 54,000 shares of common stock through the conversion of Restricted Stock Units (RSUs) on a one-for-one basis.
• Concurrently, 18,711 shares of common stock were disposed of by the Issuer to satisfy tax withholding obligations related to the RSU vesting, at a price of $0.0719 per share.
• Following these transactions, Mr. Crandall's direct beneficial ownership of common stock stands at 633,291 shares.
• He also holds 108,000 remaining Restricted Stock Units (RSUs).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were sold for tax, the underlying event is the vesting of RSUs, which increases the insider's direct ownership and aligns their interests with shareholders. This is a routine compensation event.

Positives

• The acquisition of 54,000 common shares through RSU conversion increases the Chief Commercial Officer's direct stake in the company, aligning his interests with shareholders.

Negatives

• 18,711 shares were disposed of to cover tax withholding obligations, which is a common practice but represents a reduction in the total shares held by the insider.

Future Outlook

The remaining 108,000 Restricted Stock Units (RSUs) held by the Chief Commercial Officer are scheduled to vest in two equal installments on December 8, 2025, and June 8, 2026.

Industry Context

This filing is a routine insider transaction report (Form 4) and does not provide broader industry context or trends. It reflects a standard compensation event for an executive in the cannabis industry.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership by a key executive may be viewed positively as it aligns management's interests with shareholder value. The tax-related disposition is a standard practice and generally has minimal impact.

Next Steps

• Future vesting of 108,000 Restricted Stock Units in two equal installments on December 8, 2025, and June 8, 2026.

Key Dates

Keywords

Marimed Inc., MRMD, Ryan Crandall, Chief Commercial Officer, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Ownership, Beneficial Ownership